In the last 90 days, Damora Therapeutics, Inc. insiders filed 1 open-market purchase and 0 sales; 104 institutions reported holding it in 13F filings for Q2 2026, worth $1.67B in total; Viking Global Investors is the only superinvestor holding it.
SEC filings
10-K, 10-Q, 8-K, 20-F and 40-F reports Damora Therapeutics, Inc. filed with the SEC, newest first.
Livermore lists each filing's form, 8-K items and dates only. To read a filing, open it on SEC.gov; an 8-K's press release or other attachments, such as exhibit 99.1 for Item 2.02, are in the filing index.
1.01Item 1.01: Entry into a material definitive agreement3.03Item 3.03: Material modification to the rights of security holders5.03Item 5.03: Amendment to the articles of incorporation or bylaws; change in fiscal year7.01Item 7.01: Regulation FD disclosure9.01Item 9.01: Financial statements and exhibits
2.02Item 2.02: Results of operations and financial condition (earnings release)5.03Item 5.03: Amendment to the articles of incorporation or bylaws; change in fiscal year7.01Item 7.01: Regulation FD disclosure9.01Item 9.01: Financial statements and exhibits
5.02Item 5.02: Departure or appointment of directors or officers; executive pay arrangements5.03Item 5.03: Amendment to the articles of incorporation or bylaws; change in fiscal year8.01Item 8.01: Other events9.01Item 9.01: Financial statements and exhibits
3.02Item 3.02: Unregistered sale of equity securities5.02Item 5.02: Departure or appointment of directors or officers; executive pay arrangements9.01Item 9.01: Financial statements and exhibits
1.01Item 1.01: Entry into a material definitive agreement2.01Item 2.01: Completion of an acquisition or disposition of assets3.02Item 3.02: Unregistered sale of equity securities5.02Item 5.02: Departure or appointment of directors or officers; executive pay arrangements5.03Item 5.03: Amendment to the articles of incorporation or bylaws; change in fiscal year7.01Item 7.01: Regulation FD disclosure9.01Item 9.01: Financial statements and exhibits
1.01Item 1.01: Entry into a material definitive agreement2.01Item 2.01: Completion of an acquisition or disposition of assets3.02Item 3.02: Unregistered sale of equity securities5.02Item 5.02: Departure or appointment of directors or officers; executive pay arrangements5.03Item 5.03: Amendment to the articles of incorporation or bylaws; change in fiscal year7.01Item 7.01: Regulation FD disclosure9.01Item 9.01: Financial statements and exhibits
2.05Item 2.05: Costs of exit or disposal activities (restructuring)5.02Item 5.02: Departure or appointment of directors or officers; executive pay arrangements8.01Item 8.01: Other events9.01Item 9.01: Financial statements and exhibits
